Krystal Biotech Inc.(KRYS)今日盘前大涨5.02%,引发市场关注。
分析师机构Chardan Capital发布研报,维持该公司股票评级为"买入",同时将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。
Krystal Biotech是一家临床阶段的基因疗法公司,专注于开发新型生物疫苗。公司最近取得了一些研发进展,这可能是分析师上调评级目标价的主要原因。总体来说,市场对该公司长期增长潜力充满信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.